In the case of HER2-negative breast cancer, the NCT04595565 trial allocated patients with residual lesions post-neoadjuvant chemotherapy into two groups: one receiving SG and the other receiving the treatment of the physician’s choice (TPC) in a 1:1 ratio. This evidence concerns the gene ERBB2 and breast carcinoma.